决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Retraction notice to "Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer" [Canc. Lett. 520 (2021) 385-399].
本文已被撤稿:请参阅 Elsevier 文章撤稿政策(https://www.elsevier.com/about/our-business/policies/article-withdrawal)。
本文已被撤回:请参阅 Elsevier 文章撤回政策(https://www.elsevier.com/about/our-business/policies/article-withdrawal)。应主编要求,本文已被撤回。在上述文章发表后,编辑收到通知称发生了一个错误,所有图像均以错误版本发表。编辑已决定,该稿件以其当前形式不再可接受,通过更正也不可接受,因为对图表和出版物进行大量修改会给读者带来歧义。因此,我们决定从 Cancer Letters 撤回该稿件,并有可能在同行评审后以更正后的形式重新投稿和重新发表该稿件。
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. Following the publication of the above article, the Editor was notified that an error occurred in which all images were published with incorrect versions. The Editor has taken the decision that the manuscript is no longer acceptable in its current form, nor with a corrigendum, as the extensive changes to the figures and publication would lead to ambiguity for our readers. We have therefore made the decision to retract this manuscript from Cancer Letters with the possibility of resubmission and republication of the manuscript in its corrected form after peer review.
MEMBER ACCOUNT
登录成功会直接打开下一页。